SCHEMBL4018095

SCHEMBL4018095

Nc1cnc(-c2ccc(C(F)(F)F)cc2)c(N)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.47
MKNK1 Q9BUB5 1/20 0.46
MKNK2 Q9HBH9 1/20 0.46
KIF11 P52732 2/20 0.46
DPP4 P27487 1/20 0.44
MYC P01106 1/20 0.41
WDR5 P61964 1/20 0.41
MET P08581 1/20 0.41
HEXA P06865 1/20 0.41
HEXB P07686 1/20 0.41
FEN1 P39748 3/20 0.41
ALOX5AP P20292 2/20 0.41
MAP4K4 O95819 1/20 0.40
KCNH2 Q12809 1/20 0.39
NPBWR1 P48145 1/20 0.39
CDK5 Q00535 1/20 0.39
CDK5R1 Q15078 1/20 0.39
PIM1 P11309 1/20 0.39
DHFR P00374 1/20 0.38
USP7 Q93009 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11375723 0.83 MKNK1 (0.44) PLAUMKNK1MKNK2KIF11DPP4
SCHEMBL16739695 0.80 PLAU (0.60) PLAUMKNK1MKNK2KIF11DPP4
SCHEMBL27856886 0.77 KIF11 (0.50) PLAUMKNK1MKNK2KIF11DPP4
SCHEMBL30544068 0.77 KIF11 (0.50) PLAUMKNK1MKNK2KIF11DPP4
SCHEMBL10399574 0.76 CSNK1A1 (0.52) DPP4DHFR
SCHEMBL3815741 0.75 KCNH2 (0.46) PLAUMKNK1MKNK2KIF11DPP4
SCHEMBL29892848 0.75 KCNH2 (0.46) PLAUMKNK1MKNK2KIF11DPP4
SCHEMBL4690211 0.73 CNR1 (0.60) KIF11DPP4METFEN1ALOX5AP
SCHEMBL6722240 0.72 KMT2A (0.55) DPP4DHFR
SCHEMBL9951105 0.71 FEN1 (0.60) KIF11FEN1ALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009089042-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2009-07-16 WO claimed
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2020-03-10 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B PLAU 4464/4885MKNK1 592/4885MKNK2 613/4885
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors BMI1, BAZ2A, BAZ2B PLAU 4464/4885MKNK1 592/4885MKNK2 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.